“We have observed that in fibroblasts from patients with this duplication mutation, administration of hydralazine , an iron-chelating agent, and ascorbate , a cofactor for LH activity, stimulates LH activity and its mRNA significantly more than in other EDS VI patients who do not have this duplication.”